

Nitish R. Mahapatra, Ph.D., FNASc., FAHA

Department of Biotechnology
Indian Institute of Technology Madras
Chennai 600036, India
Tel: +91-44-2257-4128
e-mail: nmahapatra@iitm.ac.in
web: <https://biotech.iitm.ac.in/faculty/nitish-r-mahapatra/>
ResearcherID: D-4123-2014
ORCID ID: 0000-0002-0695-3510
Scopus Author ID: 7004619879
Google Scholar ID: jfqJvNQAAAAJ
Vidwan ID: 51085

Date of Birth: January 9, 1971

Educational Background:

Ph.D.: Molecular Biology, Indian Institute of Chemical Biology, Kolkata (1999)

M.Sc.: Chemistry, University of Calcutta, Kolkata (1992)

B.Sc.: Chemistry, University of Calcutta, Kolkata (1990)

Career Profile:

Professor: Department of Biotechnology, Indian Institute of Technology Madras, Chennai (July 2015- present).

Visiting Professor: Department of Clinical Medicine, University of Tsukuba, Tsukuba, Japan (May-June, 2019).

Visiting Professor: Department of Biochemistry & Molecular Biology, New York Medical College, USA (September 2016-June 2017).

Associate Professor: Department of Biotechnology, Indian Institute of Technology Madras, Chennai (June 2010- July 2015).

Assistant Professor: Department of Biotechnology, Indian Institute of Technology Madras, Chennai (February 2007- May 2010).

Faculty Scientist (Assistant Professor Rank): Department of Medicine, University of California San Diego, USA (November 2004 - January 2007).

Post-doctoral Fellow: Department of Medicine, University of California San Diego, USA (January 1999 - October 2004).

Honours & Awards:

- Elected as **Fellow of the American Heart Association** (2021)
- Elected as **Fellow of the National Academy of Sciences, India** (2019)
- **JSPS (Japan Society for the Promotion of Science) Invitational Fellowship** (2019)
- **C. R. Krishna Murthi Award** for the year 2018 from the Society of Biological Chemists (India)
- **Torrent Research Award** from the International Society for Heart Research-Indian Section (2018).
- **Fulbright-Nehru Academic and Professional Excellence Fellowship** (2016).
- Session (entitled “Nitric Oxide: new oil for the heart?”) Chair, July 3, 2013 at the ISHR 21st World Congress, San Diego, USA.
- Travel Award from the International Society for Heart Research (ISHR) for attending the ISHR 21st World Congress, San Diego, June 30-July 4, 2013.
- Travel Grant from the DST, Govt. of India for attending the 10th International Catecholamine Symposium at Asilomar, California, USA (August, 2012).
- Post-doctoral Research Fellowship from the National Institutes of Health, USA (1999-2004).
- Junior and Senior Research Fellowships, CSIR, Govt. of India (1994-1998).
- Qualified in the National Eligibility Test (NET) under CSIR schemes (1993).
- T. S. Sterling Scholarship, Presidency College, Calcutta (1990-1992).

Affiliations in Scientific Societies:

- Life Member, Indian Society of Human Genetics (2010-)
- Life Member, International Society for Heart Research (2009-)
- Life Member, International Academy of Cardiovascular Sciences (2009-)
- Life Member, Society of Biological Chemists India (2008-)
- Executive Committee Member, International Society for Heart Research (Indian Section) (2015-)
- Member, International Society of Neurochemistry (2015-)
- Member, American Heart Association (2004, 2014-)
- Member, American Society of Human Genetics (2004)
- Member, American Society for Biochemistry and Molecular Biology (2012-)
- Member, American Society for Microbiology (2020-)

Research Publications:

1. Original Research Papers (selected from >60 articles)

1. Khan AA, Sundar P, Natarajan B, Gupta V, Arige V, Reddy SS, Barthwal MK, **Mahapatra NR**. 2021. An evolutionarily-conserved promoter allele governs HMG-

CoA reductase expression in spontaneously hypertensive rat. *J Mol Cell Cardiol* 158:140-152 ([Cover page article](#)).

2. Natarajan B, Arige V, Khan AA, Reddy SS, Barthwal MK, **Mahapatra NR**. 2021. Hypoxia-mediated regulation of mitochondrial transcription factors in renal epithelial cells: implications for hypertensive renal physiology. *Hypertens Res* 44:154-167.
3. Khan AA, Agarwal H, Reddy SS, Arige V, Natarajan B, Gupta V, Kalyani A, Barthwal MK, **Mahapatra NR**. 2020. MicroRNA-27a is a key modulator of cholesterol biosynthesis. *Mol Cell Biol* 40: e00470-19.
4. Subramanian L, Maghajothi S, Singh M, Kesh K, Kalyani A, Sharma S, Khullar M, Victor SM, Swarnakar S, Asthana S, Mullasari AS, **Mahapatra NR**. 2019. A Common Tag Nucleotide Variant in *MMP7* Promoter Increases Risk for Hypertension via Enhanced Interactions With CREB (Cyclic AMP Response Element-Binding Protein) Transcription Factor. *Hypertension* 74:1448-1459. (Featured in many news media including <https://timesofindia.indiatimes.com/city/chennai/study-finds-gene-that-triggers-hypertension/articleshow/72960922.cms>)
5. Arige V, Agarwal A, Khan AA, Kalyani A, Natarajan B, Gupta V, Reddy SS, Barthwal MK, **Mahapatra NR**. 2019. Regulation of Monoamine Oxidase B Gene Expression: Key Roles for Transcription Factors Sp1, Egr1 and CREB, and microRNAs miR-300 and miR-1224. *J Mol Biol* 431:1127-1147.
6. Subramanian L, Khan AA, Allu PKR, Kiranmayi M, Sahu BS, Sharma S, Khullar M, Mullasari AS, **Mahapatra NR**. 2017. A haplotype variant of the human chromogranin A gene (CHGA) promoter increases CHGA expression and the risk for cardiometabolic disorders. *J Biol Chem* 292:13970-13985. (Featured in the following news media: <http://www.thehindu.com/sci-tech/health/blame-it-on-the-genes/article19778751.ece>; <http://vigyanprasar.gov.in/isw/heartdisease.html>)
7. Gupta V, Kapopara PR, Khan AA, Arige V, Subramanian L, Sonawane PJ, Sasi BK, **Mahapatra NR**. 2017. Functional promoter polymorphisms direct the expression of cystathionine gamma-lyase gene in mouse models of essential hypertension. *J Mol Cell Cardiol* 102: 61-73. ([Cover page article](#))
8. Kiranmayi M, Chirasani VR, Allu PK, Subramanian L, Martelli EE, Sahu BS, Vishnuprabu D, Kumaragurubaran R, Sharma S, Bodhini D, Dixit M, Munirajan AK, Khullar M, Radha V, Mohan V, Mullasari AS, Naga Prasad SV, Senapati S, **Mahapatra NR**. 2016. Catestatin Gly364Ser variant alters systemic blood pressure and the risk for hypertension in human populations via endothelial nitric oxide pathway. *Hypertension* 68:334-347.
9. Kalyani A, Sonawane PJ, Khan AA, Subramanian L, Ehret GB, Mullasari AS, **Mahapatra NR**. 2015. Post-transcriptional regulation of reninase gene by miR-29

and miR-146 microRNAs: Implications for cardio-metabolic disorders. *J Mol Biol* 427: 2629–2646.

10. Gupta V, Khan AA, Sasi BK, **Mahapatra NR**. 2015. Molecular mechanism of monoamine oxidase A gene regulation under inflammation and ischemia-like conditions: key roles for the transcription factors GATA2, Sp1 and TBP. *J Neurochem* 134:21-38.
11. Kesh K, Subramanian L, Ghosh N, Gupta V, Gupta A, Bhattacharya S, **Mahapatra NR**, Swarnakar S. 2015. Association of MMP7–181A/G promoter polymorphism with gastric cancer risk: Influence of nicotine in differential allele-specific transcription via increased phosphorylation of CREB. *J Biol Chem* 290:14391-14406.
12. Sonawane PJ, Gupta V, Sasi BK, Kalyani A, Natarajan B, Khan AA, Sahu BS, **Mahapatra NR**. 2014. Transcriptional regulation of the novel monoamine oxidase renalase: crucial roles of transcription factors Sp1, STAT3 and ZBP89. *Biochemistry* 53:6878-6892.
13. Allu PK, Chirasani VR, Ghosh D, Mani A, Bera AK, Maji SK, Senapati S, Mulasari AS, **Mahapatra NR**. 2014. Naturally-occurring variants of the dysglycemic peptide pancreastatin: differential potencies for multiple cellular functions and structure-function correlation. *J Biol Chem* 289: 4455–4469.
14. Sasi BK, Sonawane PJ, Gupta V, Sahu BS, **Mahapatra NR**. 2014. Coordinated transcriptional regulation of *Hspa1a* gene by multiple transcription factors: crucial roles for HSF-1, NF-Y, NF- κ B and CREB. *J Mol Biol* 426:116-135.
15. Sahu BS, Obbineni JM, Sahu G, Allu PKR, Subramanian L, Sonawane PJ, Singh PK, SasiBK, Senapati S, Maji SK, Bera AK, Gomathi BS, Mulasari AS, **Mahapatra NR**. 2012. Functional genetic variants of the catecholamine-release-inhibitory peptide catestatin in an Indian population: allele-specific effects on metabolic traits. *J Biol Chem* 287: 43840-43852 (Featured in *Nature India*: <https://www.natureasia.com/en/nindia/article/10.1038/nindia.2012.177>).
16. Sahu BS, Obbineni JM, Sahu G, Singh PK, Sonawane PJ, SasiBK, Allu PKR, Maji SK, Bera AK, Senapati S, **Mahapatra NR**. 2012. Molecular interactions of the physiological anti-hypertensive peptide catestatin with the neuronal nicotinic acetylcholine receptor. *J Cell Sci* 125: 2323–2337.
17. Mahata M, Zhang K, Gayen JR, Nandi S, Brar BK, Ghosh S, **Mahapatra NR**, Taupenot L, O'Connor DT, Mahata SK. 2011. Catecholamine biosynthesis and secretion: physiological and pharmacological effects of secretin. *Cell Tissue Res* 345:87-102.

18. Jirout ML, Friese RS, **Mahapatra NR**, Mahata M, Taupenot L, Mahata SK, Křen V, Zídek V, Fischer J, Maatz H, Ziegler MG, Pravenec M, Hubner N, Aitman TJ, Schork NJ, O'Connor DT. 2010. Genetic regulation of catecholamine synthesis, storage and secretion in the spontaneously hypertensive rat. *Hum Mol Genet* 19: 2567-2580.
19. Friese RS, Gayen JR, **Mahapatra NR**, Schmid-Schonbein G, O'Connor DT, Mahata SK. 2010. Global metabolic consequences of a monogenic model of hypertension: Transcriptomic detection, pathway identification, and experimental verification of dissociated features of the metabolic syndrome. *Physiol Genomics* 40:195-207.
20. **Mahapatra NR**, Taupenot L, Courel M, Mahata SK, O'Connor DT. 2008. The trans-Golgi proteins SCLIP and SCG10 interact with chromogranin A to regulate neuroendocrine secretion. *Biochemistry* 47: 7167–7178.
21. **Mahapatra NR**, Mahata M, Mahata SK, O'Connor DT. 2006. The chromogranin A fragment catestatin: specificity, potency and mechanism to inhibit exocytotic secretion of multiple catecholamine storage vesicle co-transmitters. *J Hypertens* 24: 895-904.
22. Greenwood TA, Rao F, Stridsberg M, **Mahapatra NR**, Mahata M, Lillie EO, Mahata SK, Taupenot L, Schork NJ, O'Connor DT. 2006. Pleiotropic effects of novel trans-acting loci influencing human sympathochromaffin secretion. *Physiol Genomics* 25: 470-479.
23. **Mahapatra NR**, Mahata M, Ghosh S, Gayen JR, O'Connor DT, Mahata SK. 2006. Molecular basis of neuroendocrine cell type-specific expression of the chromogranin B gene: crucial role of the transcription factors CREB, AP-2, Egr-1 and Sp1. *J Neurochem* 99:119-133.
24. **Mahapatra NR**, O'Connor DT, Vaingankar SM, Sinha Hikim AP, Mahata M, Ray S, Staite E, Wu H, Gu Y, Dalton N, Kennedy BP, Ziegler MG, Ross J, Mahata SK. 2005. Targeted ablation of the chromogranin A gene: Elevated blood pressure rescued by the human ortholog. *J Clin Invest* 115: 1942-1952. (With editorial commentary).
25. Friese RS, Mahboubi P, **Mahapatra NR**, Mahata SK, Schork NJ, Schmid-Schoenbein GW, O'Connor DT. 2005. Common genetic mechanisms of blood pressure elevation in two independent rodent models of human essential hypertension. *Am J Hypertens* 18: 633-652.
26. Mahata SK, Mahata M, Wen G, Wong WB, **Mahapatra NR**, Hamilton BA, O'Connor DT. 2004. The catecholamine release-inhibitory “catestatin” fragment of chromogranin A: naturally occurring human variants with different potencies for

multiple chromaffin cell nicotinic cholinergic responses. *Mol Pharmacol* 66: 1180-1191.

27. **Mahapatra NR**, Mahata M, Hazra PP, McDonough PM, O'Connor DT, Mahata SK. 2004. A dynamic pool of calcium in catecholamine storage vesicles: Exploration in living cells by a novel vesicle-targeted chromogranin A/aequorin chimeric photoprotein. *J Biol Chem* 279: 51107-51121.
28. Fries RS, Mahboubi P, **Mahapatra NR**, Mahata SK, Schork NJ, Schmid-Schoenbein GW, O'Connor DT. 2004. Neuroendocrine transcriptome in genetic hypertension: multiple changes in diverse adrenal physiological systems. *Hypertension* 43: 1301-1311.
29. Wen G, Mahata SK, Cadman P, Mahata M, Ghosh S, **Mahapatra NR**, Rao F, Stridsberg M, Smith DW, Mahboubi P, O'Connor DT, Hamilton BA. 2004. Both rare and common polymorphisms contribute functional variation at *CHGA*, a regulator of catecholamine physiology. *Am J Hum Genet* 74: 197-207. (Lead article).
30. Preece NE, Nguyen M, Mahata M, Mahata SK, **Mahapatra NR**, Tsigelny I, O'Connor DT. 2004. Conformational preferences and activities of peptides from the catecholamine release-inhibitory (catestatin) region of chromogranin A. *Regul Pept* 118: 75-87.
31. Mahata SK, **Mahapatra NR**, Mahata M, Wang TC, Kennedy BP, Ziegler MG, O'Connor DT. 2003. Catecholamine secretory vesicle stimulus-transcription coupling *in vivo*: demonstration by a novel transgenic promoter/photoprotein reporter, and inhibition of secretion and transcription by the chromogranin A fragment catestatin. *J Biol Chem* 278: 32058-32067.
32. Wong C*, **Mahapatra NR***, Chitbangonsyn S, Mahboubi P, Mahata M, Mahata SK, O'Connor DT. 2003. The angiotensin II receptor (Agtr1a): Functional regulatory polymorphisms in a locus genetically linked to blood pressure variation in the mouse. *Physiol Genomics* 14: 83-93. [*equal contribution].
33. **Mahapatra NR**, Mahata M, O'Connor DT, Mahata SK. 2003. Secretin activation of chromogranin A gene transcription: identification of the signaling pathways *in cis* and *in trans*. *J Biol Chem* 278: 19986-19994.
34. Taupenot L, Harper KL, **Mahapatra NR**, Parmer RJ, Mahata SK, O'Connor DT. 2002. Identification of a novel sorting determinant for the regulated pathway in the secretory protein chromogranin A. *J Cell Sci* 115: 4827-4841.
35. Mahata M, **Mahapatra NR**, O'Connor DT, Mahata SK. 2002. Chromaffin cell catecholamine secretion: bisindolylmaleimide compounds exhibit novel and

potent antagonist effects at the nicotinic cholinergic receptor in pheochromocytoma cells. *Mol Pharmacol* 61: 1340-1347.

36. Taupenot L, Harper KL, **Mahapatra NR**, Parmer RJ, O'Connor DT. 2002. Intracellular protein trafficking into catecholamine storage vesicles: novel chimeric photoproteins visualized by deconvolution fluorescence microscopy. *Ann N Y Acad Sci* 971: 262-265.
37. Mahata SK, **Mahapatra NR**, Mahata M, O'Connor DT. 2002. Neuroendocrine cell type-specific and inducible expression of chromogranin/secretogranin genes: crucial promoter motifs. *Ann N Y Acad Sci* 971: 27-39.
38. **Mahapatra NR**, Mahata M, Datta A, Gerdes H -H, Huttner WB, O'Connor DT, Mahata SK. 2000. Neuroendocrine cell type-specific and inducible expression of the chromogranin B gene: crucial role of the proximal promoter. *Endocrinology* 141: 3668-3678.

II. Reviews and Book Chapters (selected)

1. Gupta V, Arige V, **Mahapatra NR**. 2019. Role of monoamine oxidases in heart diseases. *In: Modulation of Oxidative Stress in Heart Disease* (S. Chakraborti et al.; Eds). pp. 129-150. Springer Nature Singapore Private Limited, Singapore.
2. Mahata SK, Kiranmayi M, **Mahapatra NR**. 2018. Catestatin: A master regulator of cardiovascular functions. *Curr Med Chem* 25:1352-1374.
3. **Mahapatra NR**, Ghosh S, Mahata M, Bandyopadhyay GK, Mahata SK. 2017. Naturally Occurring Single Nucleotide Polymorphisms in Human Chromogranin A (*CHGA*) Gene: Association with Hypertension and Associated Diseases. *In: Chromogranins: from Cell Biology to Physiology and Biomedicine* (Angelone T, Cerra M & Tota B; Eds). pp. 195-211. Springer International Publishing AG, Cham, Switzerland.
4. Sonawane PJ, Sahu BS, **Mahapatra NR**. 2011. Pharmacogenomics of cardiovascular drugs. *In: Drug Design-Basics and Applications* (Doble M, Ed.). pp. 280-310. Tata-McGraw-Hill Publishers, New Delhi, India.
5. Sahu BS, Sonawane PJ, **Mahapatra NR**. 2010. Chromogranin A: a novel susceptibility gene for essential hypertension. *Cell Mol Life Sci* 67:861-874.
6. **Mahapatra NR**. 2008. Catestatin is a novel endogenous peptide that regulates cardiac function and blood pressure. *Cardiovasc Res* 80:330-338.

Major Research Grants:

Ongoing Research Projects.

(1) Centre of Excellence in Molecular Medicine. Funding agency: MHRD under IIT Madras Institute of Eminence scheme, Govt. of India (Rs. 496 lakhs; March 2021-March 2023) (**PI: Nitish R. Mahapatra**; Co-Investigators: Madhulika Dixit, Suresh Kumar Rayala, Amal Kanti Bera, Ninitha AJ).

(2) *Molecular and genetic bases of cardiovascular diseases: key roles for chromogranin A*. Funding agency: MHRD under SPARC scheme, Govt. of India (Rs. 65.27 lakhs; March 2019-March 2022) (**PI: Nitish R. Mahapatra**; Co-Investigator: Amal Kanti Bera)

(3) *Rational Designing, synthesis, structural and functional analysis of novel anti-hypertensive peptides*. Funding agency: DBT, Govt. of India (Rs. 85.35 lakhs; November 2017- November 2021). (**PI: Nitish R. Mahapatra**; Co-investigator: Sanjib Senapati).

(4) *Validation of the effects of functional genetic variations in chromogranin A locus*. Funding agency: DBT, Govt. of India (Rs. 69.59 lakhs; July 2018- Jan 2022). (**PI: Nitish R. Mahapatra**).

(5) *Regulation of mitochondrial transcription factors and mitochondrial biogenesis in essential hypertension*. Funding agency: SERB, DST, Govt. of India (Rs. 31.30 lakhs; December 2018- December 2021). (**PI: Nitish R. Mahapatra**).

Completed Research Projects.

(1) *Identification and characterization of functional polymorphisms in the physiological dysglycemic peptide pancreastatin in an Indian Population*. Funding agency: SERB, DST, Govt. of India (Rs. 50.00 lakhs; IITM Component: 32.70 lakhs; June 2014-June 2017). (**PI: Nitish R. Mahapatra**, Co-Investigators: V. Mohan and Radha Venkatesan, Madras Diabetes Research Foundation).

(2) *Regulation of the novel catecholamine-metabolizing enzyme Renalase by microRNAs*. Funding agency: DBT, Govt. of India (Rs. 58.08 lakhs; April 2013-December 2016). (**PI: Nitish R. Mahapatra**)

(3) *Transcriptional and post-transcriptional regulation of monoamine oxidase A and B*. Funding agency: DBT, Govt. of India (Rs. 68.43 lakhs; December 2012- December 2016). (PI :**Nitish R. Mahapatra**)

(4) *Regulation of HMG-CoA reductase gene by microRNAs*. Funding agency: CSIR, Govt. of India (Rs. 19.92 lakhs; November 2012-October 2015). (PI: **Nitish R. Mahapatra**)

(5) *Molecular mechanisms of regulation of the cystathionine gamma-lyase gene*. Funding agency: BRNS, DAE, Govt. of India (Rs. 24.15 lakhs; November 2011-October 2014). (PI :**Nitish R. Mahapatra**)

(6) *A structure-function correlation study to unravel the mechanism of action of human catestatin*. Funding agency: DBT, Govt. of India (Rs. 50.00 lakhs; August 2010- July 2013). (PI: **Nitish R. Mahapatra**, Co-investigator: Sanjib Senapati)

(7) *Cellular and molecular studies on interaction of the physiological anti-hypertensive peptide catestatin at the neuronal nicotinic acetylcholine receptor*. Funding agency: DST, Govt. of India (Rs. 38.85 lakhs; December 2009-December 2012). (PI: **Nitish R. Mahapatra**, Co-investigator: Amal Kanti Bera)

(8) *Identification and functional characterization of regulatory elements in the mouse Hspa1a gene*. Funding agency: DRDO, Govt. of India. (Rs. 42.16 lakhs; May 2009-October 2012). (PI: **Nitish R. Mahapatra**)

(9) *Polymorphisms in the physiological anti-hypertensive peptide catestatin in an Indian population*. Funding agency: DBT, Govt. of India. (Rs. 54.48 lakhs; November 2008-March 2012). (PI: **Nitish R. Mahapatra**, Co-investigators: Ajit Mullasari and Balashankar Gomathi, Madras Medical Mission)

(10) *Molecular characterization of functional polymorphisms in mouse HMG-CoA Reductase gene*. Funding agency: CSIR, Govt. of India. (Rs. 21.22 lakhs; April 2008-March 2011). (PI: **Nitish R. Mahapatra**)

(11) *Autonomic Pharmacodynamic Pharmacogenomics -Genetic Determinants of Pre-Synaptic Adrenergic Mechanisms: A Pharmacodynamic Approach*. Funding agency: NIH, USA. (\$1000,000; Completed in August 2005). (P.I. Daniel T. O'Connor; **Co-Investigator: Nitish R. Mahapatra**)

(12) *Sympathatic Neuroeffector Junctions & Blood Pressure*. Funding agency: NIH, USA. (\$300,000; Completed in May 2004). (P.I. Daniel T. O'Connor; **Co-Investigator: Nitish R. Mahapatra**)

Scientific Community Service:

- Invited reviewer of the following international journals:
 - *FASEB Journal*
 - *Atherosclerosis*
 - *Progress in Neurobiology*
 - *Human Molecular Genetics*
 - *Journal of Clinical Endocrinology & Metabolism*
 - *BMC Genetics*
 - *BMC Genomics*
 - *BMC Medical Genetics*
 - *Neuropeptides*
 - *Molecular and Cellular Biochemistry*
 - *Tumor Biology*
 - *PLoS One*
 - *Gene*
 - *Cell Stress and Chaperones*
 - *Circulation Journal*
 - *Process Biochemistry*
 - *Regulatory Peptides*
 - *Biomarkers*
 - *Journal of Agricultural and Food Chemistry*
 - *BioMed Research International*
 - *Contemporary Clinical Trials*
 - *Indian Journal of Medical Research*
 - *Indian Journal of Experimental Biology*
 - *Medical Science Monitor*
 - *Current Molecular Pharmacology*
 - *Postgraduate Medical Journal*
 - *Biotechnology and Applied Biochemistry*
 - *Bioprocess and Biosystems Engineering*
 - *Journal of Genetics*
 - *Journal of Endocrinology*
 - *Oncotarget*
 - *Cellular Physiology and Biochemistry*
 - *Frontiers in Molecular Neuroscience*
 - *Life Sciences*
- Invited reviewer of the following funding agencies:
 - DST, Govt. of West Bengal
 - DBT, Govt. of India
 - DST, Govt. of India
 - BRNS-DAE, Govt. of India.
 - National Science Foundation, Poland

- Editorial board member: *International Journal of Biosciences and Technology* (2008-), *Journal of the Practice in Cardiovascular Sciences* (2015-); Guest Editor: *International Journal of Hypertension* (2014).
- Faculty selection/ assessment committee member: IIT Hyderabad (July 2011), KIIT Bhubaneswar (December 2018), SRM University (July 2019).
- Member, National screening committee for short-listing of Fulbright-Nehru Doctoral and Professional Research Fellowship applicants in the area of Science and Technology (July 2011).
- Member, National Selection Committee for Fulbright-Nehru Post-doctoral Research Fellowships (October 2017).
- DBT, Govt. of India Nominee on the Institutional Biosafety Committee, University of Madras, Chennai (2016-2019).
- IIT Madras Institute Committees
 - Chairman, Biological Sciences Stream, Dept of Biotechnology (2021-)
 - Member, Board of Academic Research (2020-)
 - Chairman, Institute Animal Ethics Committee (2019-)
 - Member, Board of Alumni and Corporate Relations (2020-)
 - Member, Institute Biosafety Committee (2021-)